TapImmune, Inc. today announced that the Company will host a conference call and live audio webcast on Wednesday, May 31, 2017, at 4:30 p.m. ET, to provide a corporate and clinical update for the first quarter 2017.
TapImmune today provided its first quarterly business update, following the company’s uplisting to The NASDAQ Capital Market in the fourth quarter 2016. A public conference call and live audio webcast is scheduled for today at 4:30 pm ET.
TapImmune Announces Fully Funded Phase 2 Clinical Study of HER2-Targeted Vaccine in Early Breast Cancer
TapImmune announced that its collaborators at the Mayo Clinic, recently received a $3.7 million grant from the U.S. Department of Defense (DoD) to conduct a Phase 2 clinical study on TapImmune’s HER2/neu-targeted T-cell vaccine that will enroll women diagnosed with an early form of breast cancer called ductal carcinoma in situ (DCIS).
TapImmune today announced that the Company will host a conference call and live audio webcast on Tuesday, March 14, 2017, at 4:30 p.m. ET, to provide a corporate and clinical update for the fourth quarter and year end 2016.
It’s a dream many parents would welcome for their children: a vaccine that could prevent breast, ovarian and some lung cancers. It’s also the dream of immunology professor Dr. Keith Knutson. “The hope is we can develop vaccines before the development of cancer much in the way that we use a polio vaccine or a flu vaccine,” Dr. Knutson tells us in in his Mayo Clinic Jacksonville laboratory.
TapImmune Advances TPIV 200 Phase 2 Triple-Negative Breast Cancer Trial After Favorable DSMB Safety Review
TapImmune, Inc. (NASDAQ: TPIV) announced today it has successfully completed a multi-gram scale-up and GMP manufacturing of a second clinical lot of TPIV 200, the company’s multi-epitope T-cell vaccine targeting folate receptor alpha.
Monday on First Coast Connect we spoke with former CIA operative and author T. L. Williams about his new novel and Chinese cyber hacking. We also heard from TapImmune CEO Glynn Wilson about a breast cancer study at the Mayo Clinic. WJCT’s Indie Endeavor host Ryan Benk and 1904 Music Hall co-owner Jason Hunnicut announced a new partnership at the downtown venue.
On Friday, February 10 TapImmune is sponsoring an invite only DONNA VIP reception for The DONNA Foundation’s 10th anniversary 26.2 with DONNA Marathon weekend to raise money and awareness for the nonprofit’s groundbreaking breast cancer research and assistance to women and men living with breast cancer. The organization produces the only marathon in the U.S.…
TapImmune Expands Intellectual Property On PolyStartTM Platform For Use In Next-Generation T-Cell Vaccines
TapImmune, Inc. (NASDAQ: TPIV) today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its patent application titled, “Chimeric nucleic acid molecules with non-AUG initiation sequences and uses thereof.”
If you’re a biotech investor who has not yet heard of TapImmune, Inc. (NASDAQ: TPIV), this clinical-stage immune-oncology company is charging its way through the sector with its cutting-edge vaccine technologies that are attacking ovarian and breast cancer with a whole new vengeance.